3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯并[b]呋喃 | 796851-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯并[b]呋喃
• 中文别名: 是硼酸酯号；是硼酸酯CAS号
• 英文名称: 2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• 英文别名: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzofuran；2-(1-benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS: 796851-30-4
• 化学式: C₁₄H₁₇BO₃
• mdl: MFCD11841067
• 分子量: 244.098
• InChiKey: JSWDWMBIBSINSL-UHFFFAOYSA-N

物化性质

• 沸点：
  340.0±15.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.18
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  31.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]furan
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]furan
CAS number: 796851-30-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H17BO3
Molecular weight: 244.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯并[b]呋喃 在 过氧乙酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 溶剂黄146 为溶剂， 反应 51.0h， 生成 [3-[3-Bromo-2-[(4-methoxyphenyl)methoxy]phenyl]-1-benzofuran-2-yl] methyl carbonate
  参考文献：
  名称：

  通过Dieckmann型环化反应合成重氮酰胺A大环核。

  摘要：

  [反应：见正文] 18和30的Suzuki偶联得到9为两种阻转异构体的互变混合物。在-23℃用LDA处理得到大环酮8，产率为57％。

  DOI：

  10.1021/ol016097r
• 作为产物：
  描述：

  3-溴-1-苯并呋喃 、 频那醇硼烷 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.05h， 生成 3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯并[b]呋喃
  参考文献：
  名称：

  BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE

  摘要：

  本专利揭示了苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物以及含有这些化合物的组合物。还揭示了使用苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物以及含有这种组合物在治疗和/或预防与5-羟色胺相关的疾病，如抑郁症和焦虑症的方法。此外，还揭示了制备苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物的方法。

  公开号：

  US20090054454A1

文献信息

• A Monophosphine Ligand Derived from Anthracene Photodimer: Synthetic Applications for Palladium-Catalyzed Coupling Reactions
  作者：Xin Wang、Wei-Gang Liu、Chen-Ho Tung、Li-Zhu Wu、Huan Cong

  DOI：10.1021/acs.orglett.9b02414

  日期：2019.10.18

  an air-stable dianthracenyl monophosphine ligand (diAnthPhos) which can be prepared in two steps from commercially available anthracene derivatives. The ligand exhibits excellent efficiency for palladium-catalyzed coupling reactions. In particular, Miyaura borylation of heterocycle-containing electrophiles can be facilitated employing the diAnthPhos ligand with a broad substrate scope and low catalyst

  在这里，我们提出了一种空气稳定的二蒽基单膦配体（diAnthPhos），它可以由市售的蒽衍生物分两步制备。该配体对于钯催化的偶联反应表现出优异的效率。特别地，使用具有宽底物范围和低催化剂负载的diAnthPhos配体可以促进含杂环亲电试剂的宫浦硼化。通过对含杂芳基的底物进行一锅Miyaura硼化/ Suzuki偶联方案，进一步证明了新配体的宝贵合成效用。
• [EN] 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 5-AZAINDAZOLE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE
  申请人：MERCK PATENT GMBH

  公开号：WO2020083878A1

  公开（公告）日：2020-04-30

  The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

  本发明涉及公式（I）所述的新型5-氮杂吲唑衍生物，以及其药学上可接受的盐、溶剂化合物和前药，以及包含这些化合物的药物组合物。根据本发明的5-氮杂吲唑衍生物已被发现为高效的双重A2A/A2B腺苷受体拮抗剂，因此可以用作治疗剂，特别是用于治疗或预防过度增殖性或传染性疾病或紊乱。
• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120225863A1

  公开（公告）日：2012-09-06

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  披露的是新的杂环化合物及其组合物，以及它们作为治疗疾病药物的应用。还提供了在人类或动物主体中抑制PAS激酶（PASK）活性的方法，用于治疗如糖尿病 mellitus等疾病。
• FUSED HETEROAROMATIC PYRROLIDINONES
  申请人：Arikawa Yasuyoshi

  公开号：US20110152273A1

  公开（公告）日：2011-06-23

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L 1 , L 2 , R 1 , R 2 , R 3 , and R 4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

  本公开涉及公式1的化合物及其药学上可接受的盐，其中G、L1、L2、R1、R2、R3和R4在说明书中有定义。本公开还涉及制备公式1化合物的材料和方法，含有它们的药物组合物，以及它们在治疗涉及免疫系统和炎症的紊乱、疾病和病况，包括类风湿关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他需要抑制SYK的紊乱、疾病和病况的用途。
• Hydrogenation of Borylated Arenes
  作者：Marco Wollenburg、Daniel Moock、Frank Glorius

  DOI：10.1002/anie.201810714

  日期：2019.5.13

  abundant aryl boronic acids and their derivatives catalyzed by rhodium cyclic (alkyl)(amino)carbene (Rh–CAAC) is reported. The reaction tolerates a variety of boron‐protecting groups and provides direct access to a broad scope of saturated, borylated carbo‐ and heterocycles with various functional groups. The transformation is strategically important because the versatile saturated boronate products are

  据报道，环状（烷基）（氨基）卡宾铑（Rh–CAAC）催化了丰富的芳基硼酸及其衍生物的顺式选择性氢化。该反应可耐受各种硼保护基，并可以直接进入具有各种官能团的各种饱和，硼化的碳环和杂环。该转变在战略上很重要，因为通用的饱和硼酸酯产品很难用其他方法制备。硼基的后官能化证明了饱和环状结构单元的效用。